FDA to expedite development of two Sanofi rare disease drugs

FDA to expedite development of two Sanofi rare disease drugs

Source: 
Pharmaforum
snippet: 

The FDA has agreed to expedite development of two rare disease drugs from Sanofi.

The most significant of the two announcements is the Priority Review for avalglucosidase alfa, a potential new therapy for Pompe disease.